Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Angion Biomedica Corp.
Headquarters: Uniondale, NY, United States of America
Website: N/A
Year Founded: 1998
Status: Reverse-merged
BioCentury | Feb 1, 2024
Management Tracks
Rhodes, Manhard join Acadia
Plus: Vivodyne hires Menschik as CTO and an update from Enhanc3D
BioCentury | Dec 20, 2023
Data Byte
2023’s biotech reverse mergers
Half of the U.S.-listed biotechs that announced reverse mergers this year had been public for four years or less
BioCentury | May 5, 2023
Finance
Why Acelyrin was able to generate outsized demand for its $540M IPO
Late-stage lead program draws investors’ interest, as does veteran drug-hunting leadership
BioCentury | Jan 18, 2023
Regulation
Jan. 17 Quick Takes: Moderna now in RSV vaccine regulatory race
Plus: Leap, Flame propose merger and updates from Elicio, Angion, Huadong, CARsgen and more
BioCentury | Oct 4, 2022
Management Tracks
Sause named CEO of Roche Diagnostics
Plus Kranzler becomes CEO of Urica, and updates from Pharus, Celularity, Cerevance and more
BioCentury | Dec 11, 2021
Product Development
Dec. 10 Quick Takes: UCB’s rozanolixizumab meets in Phase III
Plus: Vifor-Angion product misses and updates from Arvinas-Pfizer, Canbridge, Totus and more
BioCentury | Oct 27, 2021
Product Development
Oct. 26 Quick Takes: CD8 Treg modulating play Mozart debuts with $55M
Angion, Cortexyme post Phase III misses, plus DNA Script, Novartis, Quanta, Exciva and more
BioCentury | Jun 30, 2021
Deals
June 29 Quick Takes: $276M series C to enable Element to scale up sequencing tools; plus Yescarta, tislelizumab, Lynparza, Roche-4D, Actemra and more
Sequencing company Element Biosciences raised a $276 million in a series C round to advance its mission of providing lower cost, accessible DNA sequencing tools for research applications. The company
BioCentury | Mar 11, 2021
Emerging Company Profile
AgomAb: antibodies driving tissue regeneration and recovery
Emerging Company Profile: argenx spinout AgomAb raises $74M series B to complete clinical POC for lead mAb and grow pipeline
BioCentury | Jan 29, 2021
Management Tracks
Bilenker leaving Lilly’s Loxo; plus updates from Orchard, Genfit, OncXerna, Medable, Neurophth, Elevian, Biofidelity, BIO
Josh Bilenker is leaving Eli Lilly and Co. (NYSE:LLY) as CEO of Loxo Oncology to explore other opportunities, Lilly CSO and SVP Daniel Skovronsky said during the pharma’s 4Q20 earnings
Items per page:
1 - 10 of 23